1812

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of

orizio Sanaritani, et al.

08/737,633 Transminovember 15, 1996

Group Art Unit:

Examiner: M. Ranjan

Date: July 30, 1997

For: IFN-BETA LIQUID FORMULATIONS

AMENDMENT TRANSMITTAL LETTER - FEE COMPUTATION

Hon. Commissioner of Patents and Trademarks Washington, D.C. 20231

Transmitted herewith is an amendment in the aboveidentified application.

_"Small Entity" status (37 C.F.R. §1.9 & §1.27) established _____previously _____by enclosed verified statement.

OFGS Check No. _____, which includes the fee of \$ -0-_ calculated below, is attached.

N	Ю.	HIGH	EST NO	Ο.									
CLAIMS AFTER		PREV	Y								7	DDIT.	
AMEN	IDMENT	PAID	FOR		EXT	'RA	PRESENT		R.	ATE			FEE
TOTAL	MINUS	20		*	=		х	(\$11	SE	or	\$22)	\$	
INDEP.	MINUS	3		**	=		х	(\$40	SE	or	\$80)	\$	
FIRST	PRESENTATION O	F MUL	CIPLE	DEPENDI	ENT	CLA	IM x	(\$130	SE	or	\$260)	\$	
	1 11 00										momat	-	

* not less than 20 ** not less than 3 In the event the actual fee is greater than the payment submitted or is inadvertently not enclosed or if any additional fee during the prosecution of this application is not paid, the Patent Office is authorized to charge the underpayment to Deposit Account No. 15-0700.

If this communication is filed after the shortened statutory time period had elapsed and no separate Petition is enclosed, the Commissioner of Patents and Trademarks is petitioned, under 37 C.F.R. §1.136(a), to extend the time for filing a response to the outstanding Office Action by the number of months which will avoid abandonment under 37 C.F.R. §1.135. The fee under 37 C.F.R. § 1.17 should be charged to our Deposit Account No. 15-0700.

Respectfully submitted,

Edward A. Meilman

Registration No.: 24,735

OSTROLENK, FABER, GERB & SOFFEN, LLP

1180 Avenue of the Americas New York, New York 10036

Telephone: (212) 382-0700

EAM:od

70556

P/42-60 (PCT

AUG 0 4 MM IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Parent Application of

Samaritani, et al.

Serial No. 08/737,633

Filed: November 15, 1996

IFN-BETA LIQUID FORMULATIONS For:

July 30, 1997

Group Art Unit: 1812

Examiner: M. Ranjan

Hon. Commissioner of Patents and Trademarks Washington, D.C. 20231

AMENDMENT

Sir:

In response to the Office Action dated May 13, 1997, please reconsider the above-identified application amended as follows:

IN THE SPECIFICATION:

Please amend the specification as follows:

line 12, after "forms", insert --,--; and Page 1, line 13, after "anti-viral" insert -activity--.

Page 6, line 7, after "beaker", insert --,--.

IN THE ABSTRACT

Please delete the Abstract in its entirety and substitute therefor the Abstract attached hereto.